Historique
Périodique
On the pharmaceuticalization of marijuana
(La marijuana, produit pharmaceutique)
Auteur(s) :
GRINSPOON, L.
Année
2001
Page(s) :
377-383
Langue(s) :
Anglais
Refs biblio. :
9
Domaine :
Drogues illicites / Illicit drugs
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Thésaurus mots-clés
CANNABIS
;
USAGE THERAPEUTIQUE
;
MEDICAMENTS
;
FABRICATION
;
INDUSTRIE DU MEDICAMENT
Note générale :
International Journal of Drug Policy, 2001, 12, (5-6), 377-383
Résumé :
ENGLISH :
Given the very limited toxicity of marijuana and the growing appreciation of its therapeutic value, it will undoubtedly find increasing application as a medicine in the coming years. But there is uncertainty about the forms in which it will be made available. Governments are hesitant to approve it because of concern about its use for nonmedical purposes and the difficulties of distributing as a medicine a substance that is already easily available. An alternative is the development of commercial cannabis pharmaceuticals that can be regulated and controlled. But pharmaceutical firms will be reluctant to invest the necessary money if they believe they cannot compete successfully with marijuana. Some of these products may have advantages over whole smoked or ingested marijuana, but most will not, and they will all be quite expensive. Ultimately, we can anticipate two medical distribution networks, a legal one for cannabinoid pharmaceuticals and an illegal one for street or homegrown marijuana. (Review's abstract)
Affiliation :
Medical Sch., Univ. Harvard, 74 Fenwood Rd, Boston, MA 02115
Etats-Unis. United States.
Etats-Unis. United States.